May 8, 2006|
Pharma: Signs of revival...
The March 2006 quarter has seen robust performances by Indian pharma companies, both in the domestic and exports markets. In this write-up, we shall analyse the performance of the Indian pharma companies under our coverage and see what lies in store for them in the future. We have not included companies such as Dr. Reddy's and Sun Pharma as they are yet to declare their results.
Domestic players: A look at the numbers
|Operating profit (EBIDTA)
|EBIDTA margin (%)
|Profit before tax
|Profit after tax/(loss)
|Net profit margin (%)
|* Includes Ranbaxy, Cipla, Wockhardt, Biocon and Nicholas|
The India story: The five companies posted a robust 29% YoY growth in total revenues during the quarter in question backed by a strong performance in the domestic markets. However, it must be noted that in the same period last year, de-stocking at the retailers' level in anticipation of VAT had led to a sharp fall in revenues. As a result, part of the robust performance this year is due to the low base effect. That said, strong growth of existing products, especially in the lifestyle segments, and increased contribution from new product launches also contributed to the topline growth.
|What does the analysis say?|
Exports scenario: Exports for the sector were a mixed bag. The generics market in the US continued to be plagued by increased competition and pricing pressure. Europe painted a mixed picture with Germany logging good growth rates in comparison to the UK, which was also prey to a competitive pricing environment. For example, while Ranbaxy's US business grew at a double digit pace, this growth was largely attributed to increase in volumes. Companies following the contract manufacturing model like Cipla witnessed superlative growth in exports. In Cipla's case, while formulations did record healthy growth, the impressive growth in bulk drugs (mainly supplied to the regulated markets) was the real show stealer. The semi regulated markets of Asia, Middle East, Russia and Africa continued to grow and contribute to the revenue streams of these companies.
Operating margins and profitability: Though margins on an overall basis expanded by 110 basis points, if one were to look at the individual snapshot, each had a different story to tell. Nicholas' margin expansion was considerable, as it had reported a negative EBIDTA margin during the March 2005 quarter. Most of these companies witnessed a significant rise in raw material costs and R&D expenditure. Ranbaxy's R&D expenditure (as a percentage of sales) declined, as the company has shifted most of its R&D in-house. Nicholas' R&D expenditure increased after the acquisition of Avecia. The savings in costs for most of these companies was mostly on the ‘other expenditure' front. Net profits of the sector grew by 30% YoY driven by strong topline growth, rise in other income and a lower tax outgo. Extraordinary items for the period included expenditure incurred by Wockhardt for due diligence of acquisition opportunities in the US.
While the fundamentals driving the generics market continue to remain strong, the brutal pricing environment is a cause for concern. It must be noted that the competition has tremendously increased, escalating the extent of price erosion. Having said that, while the competition most probably will show no signs of abating, a considerable rise in the patent expiries of blockbuster drugs in the coming years is likely to provide a breather to generic companies and boost revenues. The ability to manufacture drugs at the cheapest cost and leverage one's marketing and distributing network to increase reach will be the key to survival.
We believe that partnerships are likely to play a crucial role in driving growth. This could be in generics (contract manufacturing, authorised generics) or research (R&D collaboration, contract research, out-licensing of molecules) or custom manufacturing for innovator companies. In the domestic markets, with the introduction of the patent law and subsequent slowdown of product launches, albeit at a gradual pace, companies entering into in-licensing agreements with innovator companies will have the upper hand. This will ensure a steady flow of product launches in the domestic market.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 16, 2017
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407